• Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review
    Feb 13 2026

    Featuring an interview with Dr Sagar Lonial, including the following topics:

    • Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
    • Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
    • Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
    • Other investigational strategies for R/R MM (12:55)

    CME information and select publications

    Show more Show less
    17 mins
  • Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan Fakih
    Feb 12 2026

    Featuring an interview with Dr Marwan Fakih, including the following topics:

    • Etiology and incidence of squamous cell carcinoma of the anal canal (SCAC) (0:00)
    • Novel therapeutic strategies for the treatment of SCAC: Immunotherapy combinations and monitoring for recurrence with circulating tumor DNA assessment (4:37)
    • Perspectives on the overall survival benefit observed with first-line retifanlimab and carboplatin/paclitaxel; potential for cure for patients with SCAC (8:22)
    • Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives retifanlimab with carboplatin/paclitaxel (16:56)
    • Case: A woman in her mid 60s with recurrent unresectable metastatic SCAC receives single-agent immunotherapy (25:22)
    • Case: A woman in her 60s with previously untreated metastatic SCAC receives chemotherapy and attains a complete response (29:21)
    • Future directions for the treatment of SCAC (33:22)

    CME information and select publications

    Show more Show less
    37 mins
  • Squamous Cell Carcinoma of the Anal Canal — An Interview with Dr Marwan Fakih (Companion Faculty Lecture)
    Feb 11 2026

    Featuring a slide presentation and related discussion from Dr Marwan Fakih, including the following topics:

    • Overview of etiology, incidence and staging of squamous cell cancer of the anal canal (SCAC) (0:00)
    • Systemic therapy approaches to the management of recurrent unresectable and metastatic SCAC (6:17)
    • Available data with anti-PD-1 (pembrolizumab, nivolumab, retifanlimab) and anti-CTLA-4 (ipilimumab) agents in the management of unresectable metastatic SCAC previously treated with chemotherapy (12:59)
    • Immunotherapy combined with chemotherapy for the front-line treatment of SCAC (20:48)
    • Efficacy and safety of retifanlimab combined with carboplatin/paclitaxel as first-line treatment for SCAC in the Phase III POD1UM-303 trial (23:43)

    CME information and select publications

    Show more Show less
    37 mins
  • Prostate Cancer — Microlearning Activity 2 with Dr Rana R McKay: ESMO Congress 2025 Review
    Feb 10 2026

    Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics:

    • EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00)
    • Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05)
    • Other novel treatment strategies for patients with metastatic prostate cancer (10:31)

    CME information and select publications

    Show more Show less
    18 mins
  • Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore
    Feb 9 2026

    Featuring an interview with Dr Kathleen N Moore, including the following topics:

    • Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
    • Comparing toxicities of conventional chemotherapy and ADCs (6:26)
    • Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
    • Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
    • Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
    • Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
    • Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)

    CME information and select publications

    Show more Show less
    55 mins
  • Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore (Companion Faculty Lecture)
    Feb 9 2026

    Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics:

    • Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00)
    • Targeting folate receptor alpha with mirvetuximab soravtansine (3:59)
    • Targeting TROP2 with ADCs (9:12)
    • Targeting folate receptor alpha with ADCs (14:17)
    • Targeting cadherin-6 with ADCs (17:27)
    • Targeting HER2 with ADCs (26:12)
    • Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)

    CME information and select publications

    Show more Show less
    36 mins
  • Localized Colorectal Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium
    Feb 7 2026

    Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

    • Introduction (0:00)
    • Neoadjuvant Treatment for Localized Colorectal Cancer (CRC) — Dr Seligmann (2:39)
    • Emerging Novel Approaches to Adjuvant Treatment for Localized CRC — Dr Lieu (33:18)
    • Role of Circulating Tumor DNA Testing in Localized CRC — Dr Cohen (59:43)

    CME information and select publications

    Show more Show less
    1 hr and 31 mins
  • Immune Thrombocytopenia — ASH 2025 Review
    Feb 6 2026

    Featuring perspectives from Dr Hanny Al-Samkari, Dr Cindy Neunert and Prof Francesco Zaja, including the following topics:

    • Introduction (0:00)
    • Case: A woman in her early 30s with chronic relapsing immune thrombocytopenia (ITP) receives eltrombopag with ongoing stabilization of platelet counts — Neil Morganstein, MD (2:03)
    • Case: A woman in her late 60s with a long history of ITP controlled by eltrombopag experiences acute exacerbations — Bhavana (Tina) Bhatnagar, DO (6:42)
    • Clinical Manifestations and Initial Management of ITP — Dr Neunert (18:07)
    • Case: A woman in her early 80s with metastatic adenocarcinoma of the lung who responded to carboplatin/pemetrexed/pembrolizumab presents with ITP after 14 months of maintenance pembrolizumab — Susmitha Apuri, MD (33:14)
    • Incorporation of Thrombopoietin Receptor Agonists and Other Second-Line Therapies into ITP Management — Prof Zaja (40:19)
    • Case: A woman in her late 60s with stress cardiomyopathy and corticosteroid-refractory ITP receives rituximab followed by eltrombopag — Eric Fox, DO (1:00:44)
    • Current and Future Role of Novel Therapies in ITP — Dr Al-Samkari (1:03:47)

    CME information and select publications

    Show more Show less
    1 hr and 30 mins